LEXICON PHARMACEUTICALS, INC.
LXRXLexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Drugs in Pipeline
15
Phase 3 Programs
6
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
LXRX Earnings Report
EPS Est: $-0.05 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
How LXRX's past catalysts played out
Sotagliflozin (SAR439954)
Type 2 Diabetes Mellitus
Sulfonylurea
Type 2 Diabetes Mellitus
Glimepiride
Type 2 Diabetes Mellitus
Telotristat etiprate
Carcinoid Syndrome
Insulin glargine (HOE901)
Type 2 Diabetes Mellitus
Sotagliflozin
Type 2 Diabetes Mellitus
LX7101 (0.125%)
Primary Open-angle Glaucoma
LX1031 High Dose
Irritable Bowel Syndrome
LX9211
Diabetic Peripheral Neuropathy
LX9211 (blinded)
Diabetic Peripheral Neuropathic Pain
LX4211 Low Dose
Type 2 Diabetes Mellitus
LX3305 low dose
Rheumatoid Arthritis
75 mg LX4211
Type 2 Diabetes Mellitus
250 mg LX1033 tablets
Irritable Bowel Syndrome
LX6171 High Dose
Age-Related Memory Disorders
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sotagliflozin (SAR439954) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Sulfonylurea | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Telotristat etiprate | Phase 3 | Carcinoid Syndrome | - | - |
Insulin glargine (HOE901) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Sotagliflozin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
LX7101 (0.125%) | Phase 2 | Primary Open-angle Glaucoma | - | - |
LX1031 High Dose | Phase 2 | Irritable Bowel Syndrome | - | - |
LX9211 | Phase 2 | Diabetic Peripheral Neuropathy | - | - |
LX9211 (blinded) | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
LX4211 Low Dose | Phase 2 | Type 2 Diabetes Mellitus | - | - |
LX3305 low dose | Phase 2 | Rheumatoid Arthritis | - | - |
75 mg LX4211 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
250 mg LX1033 tablets | Phase 2 | Irritable Bowel Syndrome | - | - |
LX6171 High Dose | Phase 2 | Age-Related Memory Disorders | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in LEXICON PHARMACEUTICALS, INC.'s drug pipeline?→
CatalystAlert tracks 15 drug candidates in LEXICON PHARMACEUTICALS, INC.'s (LXRX) pipeline across Phase 3, Phase 2. Its lead program is Sotagliflozin (SAR439954) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LEXICON PHARMACEUTICALS, INC.'s next FDA catalyst?→
LEXICON PHARMACEUTICALS, INC.'s (LXRX) next tracked catalyst is a Phase 3 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LXRX biotech catalysts?→
Add LXRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LEXICON PHARMACEUTICALS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.